- 
                    Lung emphysema and impaired macrophage elastase clearance in mucolipin 3 deficient mice
                    On 14 January 2022, Christian Grimm, Ludwig-Maximilians-University, Munich, Germany, and his team published a paper tittled “Lung emphysema and impaired macrophage elastase clearance in mucolipin 3 deficient mice” in NATURE COMMUNICATIONS , which suggested that TRPML3 represents a key regulator of MMP-12 clearance by alveolar macrophages and may serve as therapeutic target for emphysema and chronic obstructive pulmonary disease.The kits [ELISA Kit for Matrix Metalloproteinase 12 (MMP12), SEA402Mu] of Cloud-Clone brand was chosed in this article, we are so proud for supporting the reaserchers.Lung emphysema and chronic bronchitis are the two most common causes of chronic obstructive...... 
- 
                    New discovery of COPD disease mechanism
                    Chronic obstructive pulmonary disease (COPD) is now the third most common cause of death in the world. COPD is characterized by progressive airflow obstruction and continuously aggravated airflow limitation with an abnormal and persistent inflammatory response of the lungs or airways to cigarette smoking or harmful gases and particles. Tobacco smoking and second-hand exposure to cigarette smoke (CS), are the major causes of COPD in developed countries, but air pollution and other exposures are also important.New discovery of COPD disease mechanismThere is no cure for COPD, and current treatments, including physiotherapeutic and pharmacologic interventions, aim to mitigate symptoms and ...... 
- 
                    Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis
                    On December 7, 2021, J. Paul Simons, Division of Medicine, University College London, and his team published a paper tittled “Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis”in NATURE COMMUNICATIONS , which reported a mouse model of cardiac ATTR amyloidosis with human TTRS52Ptransgenic expression.The kits [ELISA Kit for Thyroid Stimulating Hormone (TSH), CEA463Mu] of Cloud-Clone brand was chosed in this article, we are so proud for supporting the reaserchers.Cardiac ATTR amyloidosis, a serious but much under-diagnosed form of cardiomyopathy, is caused by deposition of amyloid fibrils derived from the plasma protein transthyretin...... 
- 
                    Recent advances in the mechanism of acute myeloid leukemia
                    Acute myeloid leukemia (AML) is a fatal form of hematopoietic malignancyby abnormal hematopoietic maturation, uncontrolled cellular proliferation,with 5-year survival rate of adult patients only 24%.Chemotherapy is standard-of-care, but therapeutic regimens have not changed dramatically in several decades and are often poorly tolerated.Despite the progress of therapeutic approaches such as allogeneic hematopoietic stem cell transplantation (allo-HSCT) and chimeric antigen receptor (CAR) T cell treatment, the survival of AML patients has not been significantly improved. Novel treatments for AML are urgently needed. Therefore, further understanding of the pathogenesis of AML may contribu...... 
- 
                    GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity
                    On December 1, 2021, Congwen Wei, Beijing Institute of Biotechnology, Academy of Military Medical Sciences, and his team published an article titled “GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity” in NATURE COMMUNICATIONS, which revealed a pathophysiological role of GP73 in triggering non-obese NAFLD.The kits [ELISA Kit for Apolipoprotein B (APOB), SEC003Mu;Polyclonal Antibody to Apolipoprotein B100 (APOB100), PAA603Mu01;ELISA Kit for Albumin (ALB), CEB028Mu;ELISA Kit for Apolipoprotein E (APOE), SEA704Mu;ELISA Kit for Apolipoprotein A1 (APOA1), SEA519Mu;ELISA Kit for Triglyceride (...... 
- 
                    Targeting insulin resistance to treat metabolic diseases
                    Metabolic diseases, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), hyperlipidemia, and gout, have become major public health issues worldwide.Current therapy for metabolic diseases includes lifestyle interventions, balanced diet, appropriate exercise, and the use of pharmacological drugs. However, these drugs still have some limitations because of adverse effects.Targeting insulin resistance to treat metabolic diseasesInsulin resistance(IR) is a common pathophysiological condition in which patients present with reduced insulin sensitivity and thus glucose intolerance, andunable to obtain to process the required energy from glucose to maintain cellular metabolic...... 
